



Brussels, XXX
[...] (2019) XXX draft

ANNEX

ANNEX

to the

Commission Delegated Regulation (EU) ../..

**of XXX amending for the purposes of its adaptation to technical and scientific progress,
Regulation (EC) No 1272/2008 of the European Parliament and of the Council on
classification, labelling and packaging of substances and mixtures**

ANNEX

Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

(1) Part 1 is amended as follows:

In point 1.3.1.1, the following notes J, K, L, M, N, P and R are amended as follows :

‘Note J:

The harmonised classification as a carcinogen or mutagen applies unless it can be shown that the substance contains less than 0,1 % w/w benzene (EINECS No 200-753-7), in which case a classification in accordance with Title 2 shall be performed also for these hazard classes.’

‘Note K:

The harmonised classification as a carcinogen or mutagen applies unless it can be shown that the substance contains less than 0,1 % w/w 1,3-butadiene (EINECS No 203-450-8), in which case a classification in accordance with Title 2 shall be performed also for these hazard classes. If the substance is not classified as a carcinogen or mutagen, at least the precautionary statements (P102-)P210-P403 should apply.’

‘Note L:

The harmonised classification as a carcinogen applies unless it can be shown that the substance contains less than 3% DMSO extract as measured by IP 346 (‘Determination of polycyclic aromatics in unused lubricating base oils and asphaltene free petroleum fractions – Dimethyl sulphoxide extraction refractive index method’, Institute of Petroleum, London), in which case a classification in accordance with Title 2 shall be performed also for these hazard classes.’

‘Note M:

The harmonised classification as a carcinogen applies unless it can be shown that the substance contains less than 0,005 % w/w benzo[a]-pyrene (EINECS No 200-028-5), in which case a classification in accordance with Title 2 shall be performed also for these hazard classes.’

‘Note N:

The harmonised classification as a carcinogen applies unless the full refining history is known and it can be shown that the substance from which it is produced is not a carcinogen, in which case a classification in accordance with Title 2 shall be performed also for these hazard classes.’

‘Note P:

The harmonised classification as a carcinogen or mutagen applies unless it can be shown that the substance contains less than 0,1 % w/w benzene (EINECS No 200-753-7), in which case a classification in accordance with Title 2 shall be performed also for these hazard classes. When the substance is not classified as a carcinogen or mutagen at least the precautionary statements (P102-)P260-P262-P301 + P310-P331 should apply.’

‘Note R:

The classification as a carcinogen need not apply to fibres with a Length Weighted Geometric Mean Diameter (LWGMD) minus two standard geometric errors greater than 6 µm, as measured in accordance with Part A of the Annex to Commission Regulation (EC) No 440/2008.’

(2) In Part 3, Table 3 is amended as follows:

(a) The following entries are inserted:

Index No	Chemical name	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors and ATE	Notes
				Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)		
‘007-030-00-3	nitric acid ...% [C ≤ 70 %]	231-714-2	7697-37-2	Ox. Liq. 3 Acute Tox. 3 Skin Corr. 1A	H272 H331 H314	GHS03 GHS06 GHS05 Dgr	H272 H331 H314	EUH071	Ox. Liq. 3; H272: C ≥ 65 % inhalation: ATE = 2.65 mg/L (vapours) Skin Corr. 1A; H314: C ≥ 20 % Skin Corr. 1B; H314: 5 % ≤ C < 20 %	B
‘014-048-00-5	silicon carbide fibres (with diameter < 3 µm, length > 5 µm and aspect ratio ≥ 3:1)	206-991-8	409-21-2 308076-74-6	Carc. 1B	H350i	GHS08 Dgr	H350i			

'014-049-00-0	trimethoxyvinylsilane; trimethoxy(vinyl)silane	220-449-8	2768-02-7	Skin Sens. 1B	H317	GHS07 Wng	H317'			
'014-050-00-6	tris(2-methoxyethoxy)vinylsilane; 6-(2-methoxyethoxy)-6-vinyl-2,5,7,10- tetraoxa-6-silaundecane	213-934-0	1067-53-4	Repr. 1B	H360FD	GHS08 Dgr	H360FD'			
'016-098-00-3	dimethyl disulphide	210-871-0	624-92-0	Flam. Liq. 2 Acute Tox. 3 Acute Tox. 3 STOT SE 3 STOT SE 1 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H225 H331 H301 H370 (upper respiratory tract, inhalation) H319 H317 H400 H410	GHS02 GHS06 GHS09 Dgr	H225 H331 H301 H336 H370 (upper respiratory tract, inhalation) H319 H317 H410		inhalation: ATE = 5 mg/L (vapours) oral: ATE = 190 mg/kg bw [¶] M=1 M=10'	
'029-024-00-X	granulated copper; [particle length: from 0.9 mm to 6.0 mm; particle width: from 0.494 to 0.949 mm]	231-159-6	7440-50-8	Aquatic Chronic 2	H411	GHS09	H411			Note ¹ ,
'029-025-00-5	bis(<i>N</i> -hydroxy- <i>N</i> - nitrosocyclohexylaminato- <i>O,O'</i>)copper; bis(<i>N</i> -cyclohexyl-diazenium-dioxy)- copper; [Cu-HDO]	239-703-4	312600-89-8 15627-09-5	Flam. Sol. 1 Acute Tox. 4 STOT RE 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H228 H302 H373 (liver) H318 H400 H410	GHS02 GHS07 GHS08 GHS05 GHS09 Dgr	H228 H302 H373 (liver) H318 H410		oral: ATE = 360 mg/kg bw [¶] M=1 M=1'	
'050-031-00-9	dioctyltin dilaurate; [1] stannane, dioctyl-, bis(coco acyloxy) derivs. [2]	222-883-3 [1] 293-901-5 [2]	3648-18-8 [1] 91648-39-4 [2]	Repr. 1B STOT RE 1	H360D H372 (immune system)	GHS08 Dgr	H360D H372 (immune system)'			
'601-092-00-0	dibenzo[<i>def,p</i>]chrysene; dibenzo[<i>a,l</i>]pyrene	205-886-4	191-30-0	Carc. 1B Muta. 2	H350 H341	GHS08 Dgr	H350 H341		Carc. 1B; H350; C ≥ 0,001 %'	

¹ RAC recommended a Note to be included which defines the dimension of the granules. Particle size ranges have been included below the chemical name for information.

'603-237-00-3	ipconazole (ISO); (1 <i>RS</i> ,2 <i>SR</i> ,5 <i>RS</i> ;1 <i>RS</i> ,2 <i>SR</i> ,5 <i>SR</i>)-2-(4-chlorobenzyl)-5-isopropyl-1-(1 <i>H</i> -1,2,4-triazol-1-ylmethyl)cyclopentanol	-	125225-28-7 115850-69-6 115937-89-8	Repr. 1B Acute Tox. 4 STOT RE 2 Aquatic Chronic 1	H360D H302 H373 (eyes, skin, liver) H410	GHS08 GHS07 GHS09 Dgr	H360D H302 H373 (eyes, skin, liver) H410		oral: ATE = 500 mg/kg bw M=100'	
'603-238-00-9	bis(2-(2-methoxyethoxy)ethyl)ether; tetraglyme	205-594-7	143-24-8	Repr. 1B	H360FD	GHS08 Dgr	H360FD'			
'603-239-00-4	paclobutrazol (ISO); (2 <i>RS</i> ,3 <i>RS</i>)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1 <i>H</i> -1,2,4-triazol-1-yl)pentan-3-ol	-	76738-62-0	Repr. 2 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H361d H332 H302 H319 H400 H410	GHS08 GHS07 GHS09 Wng	H361d H332 H302 H319 H410		inhalation: ATE = 3.13 mg/L (dusts and mists) oral: ATE = 490 mg/kg bw M=10 M=10'	
'603-240-00-X	2,2-bis(bromomethyl)propane-1,3-diol	221-967-7	3296-90-0	Carc. 1B Muta. 1B	H350 H340	GHS08 Dgr	H350 H340'			
'603-241-00-5	geraniol; (2 <i>E</i>)-3,7-dimethylocta-2,6-dien-1-ol	203-377-1	106-24-1	Skin Sens. 1	H317	GHS07 Wng	H317'			
'605-041-00-3	2-(4- <i>tert</i> -butylbenzyl)propionaldehyde	201-289-8	80-54-6	Repr. 1B	H360Fd	GHS08 Dgr	H360Fd'			
'607-738-00-8	MCPA-thioethyl (ISO); S-ethyl (4-chloro-2-methylphenoxy)ethanethioate; S-ethyl 4-chloro- <i>o</i> -tolylxythioacetate	246-831-4	25319-90-8	Acute Tox. 4 STOT RE. 2 Aquatic Acute 1 Aquatic Chronic 1	H302 H373 (liver) H400 H410	GHS07 GHS08 GHS09 Wng	H302 H373 (liver) H410		oral: ATE = 450 mg/kg bw M=10 M=10'	
'607-740-00-9	diisooctyl phthalate	248-523-5	27554-26-3	Repr. 1B	H360FD	GHS08 Dgr	H360FD'			
'607-741-00-4	4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5 <i>H</i>)-one; flupyradifurone	-	951659-40-8	Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1	H302 H373 (muscle) H400 H410	GHS07 GHS08 GHS09 Wng	H302 H373 (muscle) H410		oral: ATE = 500 mg/kg bw M=10 M=10'	
'607-742-00-X	thien carbazone-methyl (ISO); methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 <i>H</i> -1,2,4-triazol-1-yl)carbonylsulfamoyl]-5-methylthiophene-3-carboxylate	-	317815-83-1	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M=1000 M=1000'	

'607-743-00-5	L-(+)-lactic acid; (2S)-2-hydroxypropanoic acid	201-196-2	79-33-4	Skin Corr. 1C Eye Dam. 1	H314 H318	GHS05 Dgr	H314	EUH071'		
'607-744-00-0	2-methoxyethyl acrylate	221-499-3	3121-61-7	Flam. Liq. 3 Muta. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1	H226 H341 H360FD H331 H302 H314 H318 H317	GHS02 GHS05 GHS06 GHS08 Dgr	H226 H341 H360FD H331 H302 H314 H317	EUH071	inhalation: ATE = 2.7 mg/L (vapours) oral: ATE = 404 mg/kg bw'	
'607-745-00-6	glyoxylic acid ...%	206-058-5	298-12-4	Eye Dam. 1 Skin Sens. 1B	H318 H317	GHS05 GHS07 Dgr	H318 H317			B'
'607-746-00-1	sodium <i>N</i> -(hydroxymethyl)glycinate; [formaldehyde released from sodium <i>N</i> -(hydroxymethyl)glycinate]	274-357-8	70161-44-3	Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1	H350 H341 H332 H302 H335 H315 H319 H317	GHS08 GHS07 Dgr	H350 H341 H332 H302 H335 H315 H319 H317		inhalation: ATE = 3 mg/L (dusts and mists) oral: ATE = 1050 mg/kg bw	8 9'
'611-181-00-6	potassium (oxido- <i>NNO</i> - azoxy)cyclohexane; cyclohexylhydroxydiazene 1-oxide, potassium salt; [K-HDO]	-	66603-10-9	Flam. Sol. 1 Acute Tox. 3 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2	H228 H301 H373 (liver) H315 H318 H411	GHS02 GHS06 GHS08 GHS05 GHS09 Dgr	H228 H301 H373 (liver) H315 H318 H411		oral: ATE = 136 mg/kg bw'	
'612-294-00-3	mecetronium etilsulfate; <i>N</i> -ethyl- <i>N,N</i> -dimethylhexadecan-1- aminium ethyl sulfate; mecetronium ethyl sulphate; [MES]	221-106-5	3006-10-8	Skin Corr. 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H314 H318 H400 H410	GHS05 GHS09 Dgr	H314 H410	EUH071	M=100 M=1000'	
'613-331-00-6	(2 <i>RS</i>)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1 <i>H</i> -1,2,4-triazol-1-yl)propan-2-ol; mefentrifluconazole	-	1417782-03-6	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410		M=1 M=1'	

'613-332-00-1	oxathiapiprolin (ISO); 1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1 <i>H</i> -pyrazol-1-yl]ethanone	-	1003318-67-9	Aquatic Chronic 1	H410	GHS09 Wng	H410		M=1'	
'613-333-00-7	pyrithione zinc; ¶(T-4)-bis[1-(hydroxy- .kappa.O)pyridine-2(1 <i>H</i>)-thionato- .kappa.S]zinc	236-671-3	13463-41-7	Repr. 1B Acute Tox. 2 Acute Tox. 3 STOT RE 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H330 H301 H372 H318 H400 H410	GHS08 GHS06 GHS05 GHS09 Dgr	H360D H330 H301 H372 H318 H410		inhalation: ATE = 0.14 mg/L (dusts and mists) oral: ATE = 221 mg/kg bw M=1000 M=10'	
'613-334-00-2	flurochloridone (ISO); 3-chloro-4-(chloromethyl)-1-[3-(trifluoromethyl)phenyl]pyrrolidin-2-one	262-661-3	61213-25-0	Repr. 1B Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H360FD H302 H317 H400 H410	GHS08 GHS07 GHS09 Dgr	H360FD H302 H317 H410		oral: ATE = 500 mg/kg bw¶ M=100 M=100'	
'613-335-00-8	4,5-dichloro-2-octyl-2 <i>H</i> -isothiazol-3-one; [DCOIT]	264-843-8	64359-81-5	Acute Tox. 2 Acute Tox. 4 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1	H330 H302 H314 H318 H317 H400 H410	GHS06 GHS05 GHS09 Dgr	H330 H302 H314 H317 H410	EUH071	inhalation: ATE = 0.16 mg/L oral: ATE = 567 mg/kg bw Skin Irrit. 2; H315: 0,025 % ≤ C < 5 % Eye Irrit. 2; H319: 0,025 % ≤ C < 3 % Skin Sens. 1A; H317: C ≥ 0,0015 % M=100 M=100'	
'613-336-00-3	2-methyl-1,2-benzothiazol-3(2 <i>H</i>)-one; [MBIT]	-	2527-66-4	Acute Tox. 4 Acute Tox. 3 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 2	H312 H301 H314 H318 H317 H400 H411	GHS06 GHS05 GHS09 Dgr	H312 H301 H314 H317 H410	EUH071	dermal: ATE = 1100 mg/kg bw oral: ATE = 175 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,0015 % M=1'	

'616-228-00-4	3-(difluoromethyl)-1-methyl- <i>N</i> -(3',4',5'-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide; fluxapyroxad	-	907204-31-3	Lact. Aquatic Acute 1 Aquatic Chronic 1	H362 H400 H410	GHS09 Wng	H362 H410		M=1 M=1'	
'616-230-00-5	<i>N</i> -(hydroxymethyl)acrylamide; methylolacrylamide; [NMA]	213-103-2	924-42-5	Carc. 1B Muta. 1B STOT RE 1	H350 H340 H372 (peripheral nervous system)	GHS08 Dgr	H350 H340 H372 (peripheral nervous system)'			
'616-231-00-0	5-fluoro-1,3-dimethyl- <i>N</i> -[2-(4-methylpentan-2-yl)phenyl]-1 <i>H</i> -pyrazole-4-carboxamide; 2'-[(<i>RS</i>)-1,3-dimethylbutyl]-5-fluoro-1,3-dimethylpyrazole-4-carboxanilide; penflufen	-	494793-67-8	Carc. 2 Aquatic Acute 1 Aquatic Chronic 1	H351 H400 H410	GHS08 GHS09 Wng	H351 H410		M=1 M=1'	
'616-232-00-6	iprovalicarb (ISO); isopropyl [(2 <i>S</i>)-3-methyl-1-[[1-(4-methylphenyl)ethyl]amino]-1-oxobutan-2-yl]carbamate	-	140923-17-7	Carc. 2	H351	GHS08 Wng	H351'			
'616-233-00-1	silthiofam (ISO); <i>N</i> -allyl-4,5-dimethyl-2-(trimethylsilyl)thiophene-3-carboxamide	-	175217-20-6	STOT RE 2 Aquatic Chronic 2	H373 H411	GHS08 GHS09 Wng	H373 H411'			
'650-057-00-6	Margosa, ext. [cold-pressed oil of <i>Azadirachta indica</i> seeds without shells extracted with super-critical carbon dioxide]	283-644-7	84696-25-3	Aquatic Chronic 3	H412		H412'			

- (b) (b) The entries corresponding to index numbers 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 082-014-00-7; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616-014-00-0; 617-006-00-X are replaced by the following entries respectively:

Index No	Chemical name	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors and ATE	Notes
				Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)		
'007-004-00-1	nitric acid ...% [C > 70 %]	231-714-2	7697-37-2	Ox. Liq. 2 Acute Tox. 1 Skin Corr. 1A	H272 H330 H314	GHS03 GHS06 GHS05 Dgr	H272 H330 H314	EUH071	Ox. Liq. 2; H272: C ≥ 99 % Ox. Liq. 3; H272: 70 % ≤ C < 99 %	B'
'014-018-00-1	octamethylcyclotetrasiloxane; [D4]	209-136-7	556-67-2	Repr. 2 Aquatic Chronic 1	H361f *** H410	GHS08 GHS09 Wng	H361f *** H410		M=10'	
'015-134-00-5	pirimiphos-methyl (ISO); O-[2-(diethylamino)-6-methylpyrimidin-4-yl] O,O-dimethyl phosphorothioate	249-528-5	29232-93-7	Acute Tox. 4 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1	H302 H372 (nervous system) H400 H410	GHS07 GHS08 GHS09 Dgr	H302 H372 (nervous system) H410		oral: ATE = 1414 mg/kg bw M=1000 M=1000'	
'015-181-00-1	phosphine	232-260-8	7803-51-2	Flam. Gas 1 Press. Gas Acute Tox. 1 Skin Corr. 1B Aquatic Acute 1	H220 H330 H314 H400	GHS02 GHS04 GHS06 GHS05 GHS09 Dgr	H220 H330 H314 H400		inhalation: ATE = 10 ppmV (gases)	U'
'050-021-00-4	dichlorodioctylstannane	222-583-2	3542-36-7	Repr. 1B Acute Tox. 2 STOT RE 1 Aquatic Chronic 3	H360D H330 H372 ** H412	GHS08 GHS06 Dgr	H360D H330 H372 ** H412		Repr. 1B; H360D: C ≥ 0,03 % inhalation: ATE = 0.098 mg/L (dusts and mists)'	
'050-027-00-7	2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate; [DOTE]	239-622-4	15571-58-1	Repr. 1B STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H372 (immune system) H400 H410	GHS08 GHS09 Dgr	H360D H372 (immune system) H410'			
'082-013-00-1	lead powder; ¶[particle diameter < 1 mm]	231-100-4	7439-92-1	Repr. 1A Lact. Aquatic Acute 1 Aquatic Chronic 1	H360FD H362 H400 H410	GHS08 GHS09 Dgr	H360FD H362 H410		Repr. 1A; H360D: C ≥ 0,03 % M=1 M=10'	

'082-014-00-7	lead massive; [particle diameter ≥ 1 mm]	231-100-4	7439-92-1	Repr. 1A Lact. Aquatic Acute 1 Aquatic Chronic 1	H360FD H362 H400 H410	GHS08 GHS09 Dgr	H360FD H362 H410		M=1 M=10'	
'603-014-00-0	2-butoxyethanol; ethylene glycol monobutyl ether	203-905-0	111-76-2	Acute Tox. 3 Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2	H331 H302 H315 H319	GHS06 Dgr	H331 H302 H315 H319		inhalation: ATE = 3 mg/L oral: ATE = 1200 mg/kg bw'	
'603-065-00-9	m-bis(2,3-epoxypropoxy)benzene; resorcinol diglycidyl ether	202-987-5	101-90-6	Carc. 1B Muta. 2 Acute Tox. 3 Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3	H350 H341 H311 H302 H315 H319 H317 H412	GHS08 GHS06 Dgr	H350 H341 H311 H302 H315 H319 H317 H412		dermal: ATE = 300 mg/kg bw oral: ATE = 500 mg/kg bw'	
'605-019-00-3	citral	226-394-6	5392-40-5	Skin Irrit. 2 Skin Sens. 1	H315 H317	GHS07 Wng	H315 H317'			
'607-177-00-9	tribenuron-methyl (ISO); methyl 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylcarbamoylsulfamoyl]benzoate	401-190-1	101200-48-0	STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H373 H317 H400 H410	GHS08 GHS07 GHS09 Wng	H373 H317 H410		M=100 M=100 '	
'607-256-00-8	azoxystrobin (ISO); methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yl]oxy}phenyl}-3-methoxyacrylate		131860-33-8	Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1	H331 H400 H410	GHS06 GHS09 Dgr	H331 H410		inhalation: ATE = 0.7 mg/L (dust and mist) M=10 M=10'	
'607-314-00-2	ethofumesate (ISO); (RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl methanesulfonate	247-525-3	26225-79-6	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M=1 M=1 '	
'609-041-00-4	2,4-dinitrophenol	200-087-7	51-28-5	Acute Tox. 3 * Acute Tox. 3 Acute Tox. 2 STOT RE 1 Aquatic Acute 1	H331 H311 H300 H372 H400	GHS06 GHS08 GHS09 Dgr	H331 H311 H300 H372 H400		dermal: ATE = 300 mg/kg bw oral: ATE = 30 mg/kg bw'	

'609-064-00-X	mesotrione (ISO); 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione		104206-82-8	Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1	H361d H373 (eyes, nervous system) H400 H410	GHS08 GHS09 Wng	H361d H373 (eyes, nervous system) H410		M=10 M=10'	
'613-112-00-5	octhilinone (ISO); 2-octyl-2H-isothiazol-3-one; [OIT]	247-761-7	26530-20-1	Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1	H330 H311 H301 H314 H318 H317 H400 H410	GHS06 GHS05 GHS09 Dgr	H330 H311 H301 H314 H317 H410		inhalation: ATE = 0.27 mg/L (dusts and mists) dermal: ATE = 311 mg/kg bw oral: ATE = 125 mg/kg bw Skin Sens. 1; H317: C ≥ 0,0015 % M=100 M=100'	
'613-115-00-1	hymexazol (ISO); 3-hydroxy-5-methylisoxazole	233-000-6	10004-44-1	Repr. 2 Acute Tox. 4 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2	H361d H302 H318 H317 H411	GHS08 GHS07 GHS05 GHS09 Dgr	H361d H302 H318 H317 H411		oral: ATE = 1600 mg/kg bw'	
'613-125-00-6	hexythiazox (ISO); <i>trans</i> -5-(4-chlorophenyl)-N-cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide		78587-05-0	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M=1 M=1'	
'613-202-00-4	pymetrozine (ISO); (E)-4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one		123312-89-0	Carc. 2 Repr. 2 Aquatic Chronic 1	H351 H361fd H410	GHS08 GHS09 Wng	H351 H361fd H410		M=1'	
'613-259-00-5	imiprothrin (ISO); reaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)- <i>cis</i> -chrysanthemate; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)- <i>trans</i> -chrysanthemate	428-790-6	72963-72-5	Carc. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1	H351 H332 H302 H371 (nervous system; oral, inhalation) H400 H410	GHS08 GHS07 GHS09 Wng	H351 H332 H302 H371 (nervous system; oral, inhalation) H410		inhalation: ATE = 1.4 mg/L (dusts and mists) oral: ATE = 550 mg/kg bw M=10 M=10 '	

'616-014-00-0	butanone oxime; ¶ethyl methyl ketoxime; ¶ethyl methyl ketone oxime	202-496-6	96-29-7	Carc. 1B Acute Tox. 4 Acute Tox. 3 STOT SE 3 STOT SE 1 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1¶	H350 H312 H301 H336 H370 (upper respiratory tract)H373 (blood system) H315 H318 H317 ¶	GHS08 GHS06¶ GHS05 Dgr	H350 H312¶ H301 H336 H370 (upper respiratory tract)¶H373 (blood system) H315 H318 H317		dermal: ATE = 1100 mg/kg bw oral: ATE = 100 mg/kg bw'	
'617-006-00-X	bis(α,α-dimethylbenzyl) peroxide	201-279-3	80-43-3	Org. Perox. F Repr. 1B Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 2	H242 H360D H315 H319 H411	GHS02 GHS08 GHS07 GHS09 Dgr	H242 H360D¶ H315 H319 H411'			

(c) the entries corresponding to index numbers 601-064-00-8 and 607-693-00-4 are deleted.